Organization
Second Affiliated Hospital of Guangzhou Medical University
36 clinical trials
Clinical trial
Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and IL2 for Treatment of Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Anti-cancer Neoantigen mRNA Vaccine to Treat Advanced Solid Tumors: Phase I Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2027-12-30
Clinical trial
GPC3/Mesothelin Targeted CAR-γδT for Immunotherapy of Solid Cancer: Phase I Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-11-30
Clinical trial
A Single-center, Single-arm Study of Avatrombopag for Patients With Hepatocellular Carcinoma and Thrombocytopenia Who Intend to Undergo Transarterial Chemoembolization and/or Hepatic Arterial Infusion ChemotherapyStatus: Recruiting, Estimated PCD: 2024-08-13
Clinical trial
Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy or IHC-guided Therapy for Advanced CancersStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
DEB-TACE in Combination With or Without RALOX-based HAIC for Unresectable Large Hepatocellular Carcinoma: A Single-center, Randomized, Controlled TrialStatus: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis: a Prospective, Multicenter, Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Mesothelin/GPC3/GUCY2C Targeted CAR-T for Immunotherapy of Pancreatic Cancer: Phase I Clinical TrialStatus: Recruiting, Estimated PCD: 2026-03-10
Clinical trial
A Phase II/III Randomized Trial of Comparison of Survival Benefit of Administration of PD1/PDL1/CTLA4 Inhibitors Via Neck Artery or Intratumor Versus Vein Infusion for Immunotherapy of HNCStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase I Trial to Evaluate Safety and Preliminary Efficacy of CLDN6/GPC3/Mesothelin/AXL-CAR-NK in Patients With CLDN6/GPC3/Mesothelin/AXL-positive Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Sintilimab, Bevacizumab Plus Y-90 Selective Internal Radiation Therapy for Patients With Unresectable Intermediate-advanced Hepatocellular Carcinoma: a Prospective, Single-center, Single Arm TrialStatus: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
Lenvatinib, Sintilimab Plus Y-90 Selective Internal Radiation Therapy for Patients With Unresectable Intermediate-advanced Hepatocellular Carcinoma: a Prospective, Single-center, Single Arm TrialStatus: Recruiting, Estimated PCD: 2026-01-09
Clinical trial
Anti-cancer Neoantigen Polypeptide Vaccine to Treat Advanced Solid Tumors: Phase I Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2027-12-30
Clinical trial
A Prospective, Single-arm, Single-center, Exploratory Clinical Study of Tirelizumab Combined With Chemotherapy in First-line Treatment of ECOG PS 2 Points in Relapsed/Metastatic Non-small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase II Prospective Single-arm Clinical Study of Aribulin Combined With Carboplatin and Bevacizumab in the First-line Treatment of Platinum-sensitive Recurrent Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
Carrilizumab Combined With Bevacizumab Plus Capecitabine in a Second-line Prospective, One-arm Exploratory Study of Relapsed Metastatic Squamous Cell Carcinoma of Head and NeckStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
Sintilimab, Bevacizumab Plus TACE Versus Lenvatinib Plus TACE for Advanced Stage Hepatocellular Carcinoma: A Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2027-07-31
Clinical trial
Lenvatinib, Sintilimab Plus TACE Versus Lenvatinib Plus TACE for Patients With Advanced Hepatocellular Carcinoma: a Prospective, Multicenter, Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
Transarterial Chemoembolization With Drug-eluting Beads Plus Hepatic Arterial Infusion Chemotherapy Versus Hepatic Arterial Infusion Chemotherapy Alone for Large Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2026-02-09
Clinical trial
Induced-T Cell Like NK Cellular Immunotherapy for Cancers That Are Lack of MHC-I ExpressionStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical TrialStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase II/III Randomized Trial of Comparison of Survival Benefit of Administration of PD1/PDL1 Inhibitor Via Hepatic Arterial Infusion Versus Vein for Immunotherapy of Advanced Liver CancerStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Single-arm, Open, Exploratory Clinical Study Evaluating the Safety and Efficacy of EGFR/B7H3 CAR-T in Patients With EGFR/ B7H3-positive Advanced Solid Tumors (Lung and Triple-negative Breast Cancer)Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Engineered TILs/CAR-TILs With PD1 Knockout and Anti-PD1/CTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Prospective，Single Center, Randomized Control，Phase III Clinical Study for Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Patients With Stage ⅢB-Ⅳ NSCLC Who Failed With First-line TherapyStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
TCR-T Cells Targeting Cancer Cells for Immunotherapy of Lung Cancer and Other Solid Tumors: Phase I Clinical TrialStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
Triplex CTLA4/PD1/PDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
Trametinib Combined With Everolimus and Lenvatinib in the Treatment of Recurrent/Refractory Advanced Solid Tumors: a Phase II Clinical TrialStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2033-11-01
Clinical trial
A Single-arm, Open-label, Phase I Study to Evaluate the Safety and Efficacy of CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cells in EGFR-positive Patients With Advanced Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
CAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical TrialStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Anti-cancer DC Cell Vaccination to Treat Advanced Solid Tumors: Phase I Clinical TrialStatus: Recruiting, Estimated PCD: 2030-12-30
Clinical trial
Skin Drug Prepared From Stem Cell Derived Exome for Treatment of Diabetic Foot: a Phase II Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2028-12-30
Clinical trial
Intra-tumor Delivery of Double Checkpoint Inhibitors, Chemodrug, and/or Bevacizumab Therapy as First Line for Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2030-12-30
Clinical trial
Intra-tumor Delivery of Double Checkpoint Inhibitors, Chemodrug, and/or Bevacizumab Therapy as First Line for Inoperable Lung CancerStatus: Recruiting, Estimated PCD: 2028-12-30